Sensydia

What they do

Sensydia develops the investigational Cardiac Performance System for noninvasive hemodynamic assessment using passively acquired acoustic and electrical signals and algorithmic analysis. Category III CPT code 1036T became effective July 1, 2026. The code does not establish FDA authorization or guaranteed reimbursement; the company identifies its system as investigational.

The record

Vertical

Cardiovascular

Sub-segment

Noninvasive hemodynamic assessment

Product type

Device

Stage

Not disclosed

Headquarters

Los Angeles, California, United States

Region

North America

Founded

Not disclosed

Total funding

Undisclosed